Gallant Secures $18 Million in Funding to Develop Revolutionary Stem Cell Therapy for Pets
San Diego-based startup Gallant made headlines this week with the announcement of a significant $18 million funding round. The company is on a mission to introduce the first-ever FDA-approved ready-to-use stem cell therapy for veterinary medicine, potentially revolutionizing the way we care for our beloved pets.
Gallant’s innovative approach targets various medical conditions in animals, with their initial focus on Feline Chronic Gingivostomatitis (FCGS) in cats. The company aims to obtain FDA approval for this treatment by early 2026, marking a significant milestone in the field of veterinary medicine.
The use of stem cell therapy in pets is still considered experimental, despite extensive research in the human healthcare sector over the years. Gallant’s efforts have already shown promising results in studies involving dogs with arthritis, demonstrating improvements in pain relief and mobility that can last up to two years. However, the outcomes were more varied when similar treatments were tested for kidney disease in cats, another area of interest for Gallant.
What sets Gallant apart is its emphasis on convenience. Unlike traditional stem cell treatments that require cell harvesting from the patient or compatible donors, Gallant’s therapy utilizes ready-to-use cells from donor animals, even if they belong to a different species. This approach streamlines the treatment process and offers a more accessible solution for pet owners.
Investors have recognized the potential of Gallant’s groundbreaking technology, as evidenced by the recent funding round led by Digitalis Ventures and NovaQuest Capital Management. The latter has a track record of investing in the first FDA-approved human stem cell therapy, underscoring the confidence in Gallant’s capabilities.
The Vision Behind Gallant
Gallant’s journey is marked by a compelling narrative that adds depth to its innovative endeavors. Founded by Aaron Hirschhorn, the company emerged from his previous success with DogVacay, a leading player in the online dog-sitting marketplace that was eventually acquired by Rover. Although Hirschhorn tragically passed away in 2021, his legacy lives on through Gallant, now spearheaded by Linda Black as President and Chief Scientific Officer.
With a total funding of at least $44 million from investors, Gallant is poised to make a lasting impact in the field of veterinary medicine. The company’s unique approach to stem cell therapy and its commitment to advancing pet healthcare reflect a dedication to innovation and compassion for furry companions.